News
Public · Published
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck said the European Medicines Agency's human medicines committee recommended expanding ENFLONSIA's use to prevent RSV lower respiratory tract disease in children up to 24 months old who are at increased risk of severe illness through their second RSV season. The European Commission will review the recommendation, with a decision expected within two months.
Published:
Updated:
What happened
Merck said the European Medicines Agency’s human medicines committee recommended expanding ENFLONSIA’s use to prevent RSV lower respiratory tract disease in children up to 24 months old who are at increased risk of severe illness through their second RSV season. The European Commission will review the recommendation, with a decision expected within two months.
Confirmed
Global impact / market context
If approved, the expanded age range could give Merck a larger group of children eligible for ENFLONSIA in Europe, potentially supporting additional sales. The effect depends on the Commission’s decision and subsequent use; the article provides no sales forecast or evidence of a market response.
Analyst inference
The committee’s opinion is a recommendation, not final authorization. The article says the European Commission is expected to decide within two months. It also reports that the FDA accepted a separate U.S. application for use in children under two, but gives no target decision date.
Confirmed
What to watch
- Watch for the European Commission’s final decision, expected within two months; approval would allow the proposed expanded indication in the EU, Iceland, Liechtenstein and Norway. Confirmed
- Check whether Merck reports a U.S. regulatory decision on its separate application for children under two; the supplied article gives no target date. Confirmed
- If the age expansion is approved, adoption among eligible children could shape added demand and sales, but the article does not quantify either. Analyst inference
Evidence
- Original source link unavailable